253 related articles for article (PubMed ID: 20804536)
1. Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (CMV) glycoprotein B is associated with CMV disease after renal transplantation in recipients having the same glycoprotein H serotypes as their donors.
Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Ikuta K; Kushida N; Yanagida T; Shishido K; Aikawa K; Toma H; Inoue N; Yamaguchi O; Tanabe K; Suzutani T
Transpl Infect Dis; 2011 Jun; 13(3):318-23. PubMed ID: 20804536
[TBL] [Abstract][Full Text] [Related]
2. Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes.
Ishibashi K; Tokumoto T; Tanabe K; Shirakawa H; Hashimoto K; Kushida N; Yanagida T; Inoue N; Yamaguchi O; Toma H; Suzutani T
Clin Infect Dis; 2007 Jul; 45(1):60-7. PubMed ID: 17554702
[TBL] [Abstract][Full Text] [Related]
3. Association between antibody response against cytomegalovirus strain-specific glycoprotein H epitopes and HLA-DR.
Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Kushida N; Yanagida T; Shishido K; Aikawa K; Yamaguchi O; Toma H; Tanabe K; Suzutani T
Microbiol Immunol; 2009 Jul; 53(7):412-6. PubMed ID: 19563400
[TBL] [Abstract][Full Text] [Related]
4. The presence of antibodies against the AD2 epitope of cytomegalovirus glycoprotein B is associated with acute rejection after renal transplantation.
Ishibashi K; Tokumoto T; Shirakawa H; Oguro T; Yanagida T; Takahashi N; Nomiya M; Haga N; Aikawa K; Tanabe K; Inoue N; Kojima Y; Suzutani T
Microbiol Immunol; 2014 Jan; 58(1):72-5. PubMed ID: 24215540
[TBL] [Abstract][Full Text] [Related]
5. Reinfection of cytomegalovirus in renal transplantation.
Ishibashi K; Yamaguchi O; Suzutani T
Fukushima J Med Sci; 2011; 57(1):1-10. PubMed ID: 21701077
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus (CMV) glycoprotein H-based serological analysis in Japanese healthy pregnant women, and in neonates with congenital CMV infection and their mothers.
Ikuta K; Minematsu T; Inoue N; Kubo T; Asano K; Ishibashi K; Imamura T; Nakai H; Yoshikawa T; Moriuchi H; Fujiwara S; Koyano S; Suzutani T
J Clin Virol; 2013 Oct; 58(2):474-8. PubMed ID: 23916379
[TBL] [Abstract][Full Text] [Related]
7. Is combined pretransplantation seropositivity of kidney transplant recipients for cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection?
Essa S; Pacsa A; Said T; Nampoory MR; Raghupathy R; Johny KV; Al-Nakib W; Al-Mosawy M
Med Princ Pract; 2008; 17(1):66-70. PubMed ID: 18059104
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
9. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease.
Manuel O; Asberg A; Pang X; Rollag H; Emery VC; Preiksaitis JK; Kumar D; Pescovitz MD; Bignamini AA; Hartmann A; Jardine AG; Humar A
Clin Infect Dis; 2009 Oct; 49(8):1160-6. PubMed ID: 19751151
[TBL] [Abstract][Full Text] [Related]
10. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.
Boppana SB; Rivera LB; Fowler KB; Mach M; Britt WJ
N Engl J Med; 2001 May; 344(18):1366-71. PubMed ID: 11333993
[TBL] [Abstract][Full Text] [Related]
11. [Genotyping of viral glycoprotein B (gB) in hematopoietic stem cell transplant recipients with active cytomegalovirus infection: analysis of the impact of gB genotypes on the patients' outcome].
Roubalová K; Strunecký O; Zufanová S; Procházka B; Vitek A
Epidemiol Mikrobiol Imunol; 2010 Apr; 59(2):92-9. PubMed ID: 20586171
[TBL] [Abstract][Full Text] [Related]
12. A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?
Ohlin M
Mol Immunol; 2014 Aug; 60(2):95-102. PubMed ID: 24802891
[TBL] [Abstract][Full Text] [Related]
13. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
14. Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant.
Muñoz I; Gutiérrez A; Gimeno C; Farga A; Alberola J; Solano C; Prósper F; García-Conde J; Navarro D
J Med Virol; 2001 Sep; 65(1):77-84. PubMed ID: 11505447
[TBL] [Abstract][Full Text] [Related]
15. Strain-specific seroepidemiology and reinfection of cytomegalovirus.
Ishibashi K; Tokumoto T; Shirakawa H; Hashimoto K; Kushida N; Yanagida T; Shishido K; Aikawa K; Yamaguchi O; Toma H; Tanabe K; Suzutani T
Microbes Infect; 2008 Oct; 10(12-13):1363-9. PubMed ID: 18761415
[TBL] [Abstract][Full Text] [Related]
16. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?
Saghafi H; Qorashi M; Heidari A
Transplant Proc; 2009 Sep; 41(7):2761-3. PubMed ID: 19765428
[TBL] [Abstract][Full Text] [Related]
17. Characterization of antibody response to human cytomegalovirus in Indian renal transplant patients.
Finny GJ; Rao M; Mach M; Juneja R; Thomas PP; Jacob CK; Manayani DJ; Abraham P; Abraham M; Sridharan G
Indian J Med Res; 2001 Jun; 113():221-7. PubMed ID: 11816956
[TBL] [Abstract][Full Text] [Related]
18. Distinct genotypic distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease.
Woo PC; Lo CY; Lo SK; Siau H; Peiris JS; Wong SS; Luk WK; Chan TM; Lim WW; Yuen KY
Clin Diagn Lab Immunol; 1997 Sep; 4(5):515-8. PubMed ID: 9302197
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.
van Zanten J; van der Giessen M; van der Voort LH; van Son WJ; van der Bij W; The TH
Clin Exp Immunol; 1991 Jan; 83(1):102-7. PubMed ID: 1846328
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant glycoprotein antigens gB and gH for diagnosis of primary human cytomegalovirus infection during pregnancy.
Eggers M; Radsak K; Enders G; Reschke M
J Med Virol; 2001 Feb; 63(2):135-42. PubMed ID: 11170050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
